79 related articles for article (PubMed ID: 1981571)
1. [Rational basis for the use of alfa-2a recombinant interferon in the treatment of mycosis fungoides (MF)].
Mazza P; Bocchia M; Zinzani PL; Gherlinzoni F; Ghetti PL
Haematologica; 1990; 75 Suppl 4():78-81. PubMed ID: 1981571
[No Abstract] [Full Text] [Related]
2. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.
Simoni R; Cavalieri R; Coppola G; Ricciotti L; De Pità O; Criscuolo D; Covelli A; Papa G; Mandelli F
J Biol Regul Homeost Agents; 1987; 1(2):93-9. PubMed ID: 3504088
[TBL] [Abstract][Full Text] [Related]
3. Combination of local PUVA-therapy and interferon alpha-2A in the treatment of tumoral stage mycosis fungoides.
Delpuget-Bertin N; Bernard P; Bedane C; Dang PM; Bonnetblanc JM
Dermatology; 1996; 193(1):74-5. PubMed ID: 8864634
[No Abstract] [Full Text] [Related]
4. Interferon-alpha is effective for CD4(+), CCR4(-) mycosis fungoides.
Fujimura T; Okuyama R; Watabe A; Hashimoto A; Tagami H; Aiba S
Int J Dermatol; 2007 Apr; 46(4):435-8. PubMed ID: 17442093
[TBL] [Abstract][Full Text] [Related]
5. Evidence for HTLV-I associated with mycosis fungoides and B-cell chronic lymphocytic leukemia.
Peterman A; Jerdan M; Staal S; Bender B; Striecher H; Schüpbach J; Resnick L
Arch Dermatol; 1986 May; 122(5):568-71. PubMed ID: 2871815
[TBL] [Abstract][Full Text] [Related]
6. Effective control of rush progression of CD8+ mycosis fungoides with pegylated interferon.
Fujimura T; Okuyama R; Hashimoto A; Watanabe H; Nakagawa S; Tagami H; Aiba S
Acta Derm Venereol; 2006; 86(2):161-2. PubMed ID: 16648924
[No Abstract] [Full Text] [Related]
7. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
Spaccarelli N; Rook AH
Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
[TBL] [Abstract][Full Text] [Related]
8. CD4/CD8 double negative mycosis fungoides with PD-1 (CD279) expression--a disease of follicular helper T-cells?
Kempf W; Kazakov DV; Cipolat C; Kutzner H; Roncador G; Tomasini D
Am J Dermatopathol; 2012 Oct; 34(7):757-61. PubMed ID: 22722467
[TBL] [Abstract][Full Text] [Related]
9. HTLV-V: a new human retrovirus associated with cutaneous T-cell lymphoma (mycosis fungoides).
Fine RM
Int J Dermatol; 1988 Sep; 27(7):473-4. PubMed ID: 2906051
[No Abstract] [Full Text] [Related]
10. [The functioning of the interferon system in mycosis fungoides patients undergoing different methods of therapy].
Faradzhev ZG
Vestn Dermatol Venerol; 1990; (6):4-7. PubMed ID: 2120861
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy.
Vonderheid EC; Thompson R; Smiles KA; Lattanand A
Arch Dermatol; 1987 Jun; 123(6):757-63. PubMed ID: 3579357
[TBL] [Abstract][Full Text] [Related]
12. Imbalance of T helper and T suppressor cells and reduced plaque-forming cell capacity of mononuclear cells from patients with mycosis fungoides.
Jensen JR; Kaltoft K; Thestrup-Pedersen K
Clin Exp Dermatol; 1986 Sep; 11(5):467-74. PubMed ID: 2949896
[No Abstract] [Full Text] [Related]
13. Mycosis fungoides mimicking erysipelas.
Weyers W; Diaz-Cascajo C; Preinfalk P; Löffler H
J Dtsch Dermatol Ges; 2008 Apr; 6(4):298-301. PubMed ID: 18248497
[TBL] [Abstract][Full Text] [Related]
14. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
15. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
Wozniak MB; Tracey L; Ortiz-Romero PL; Montes S; Alvarez M; Fraga J; Fernández Herrera J; Vidal S; Rodriguez-Peralto JL; Piris MA; Villuendas Deceased R
Br J Dermatol; 2009 Jan; 160(1):92-102. PubMed ID: 18945306
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
17. Unusual variants of mycosis fungoides.
Abeldaño A; Arias M; Benedetti A; Ochoa K; Maskin M; Pellerano G; Kien MC; Chouela E
Skinmed; 2011; 9(4):218-22. PubMed ID: 21980706
[TBL] [Abstract][Full Text] [Related]
18. Multicenter photopheresis intervention trial in early-stage mycosis fungoides.
Talpur R; Demierre MF; Geskin L; Baron E; Pugliese S; Eubank K; Zic JA; Miller DR; Tharp M; Bohjanen K; Duvic M
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):219-27. PubMed ID: 21575927
[TBL] [Abstract][Full Text] [Related]
19. Poikilodermatous mycosis fungoides.
Farley-Loftus R; Mandal R; Latkowski JA
Dermatol Online J; 2010 Nov; 16(11):8. PubMed ID: 21163159
[TBL] [Abstract][Full Text] [Related]
20. Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion.
Kuzel TM; Roenigk HH; Samuelson E; Rosen ST
J Natl Cancer Inst; 1992 Jan; 84(2):119-21. PubMed ID: 1735877
[No Abstract] [Full Text] [Related]
[Next] [New Search]
